CN107156411A - 一种改善人体免疫功能的无糖清口糖 - Google Patents
一种改善人体免疫功能的无糖清口糖 Download PDFInfo
- Publication number
- CN107156411A CN107156411A CN201710325241.7A CN201710325241A CN107156411A CN 107156411 A CN107156411 A CN 107156411A CN 201710325241 A CN201710325241 A CN 201710325241A CN 107156411 A CN107156411 A CN 107156411A
- Authority
- CN
- China
- Prior art keywords
- parts
- sugar
- tasty
- oligosaccharide
- isomalt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036737 immune function Effects 0.000 title claims abstract description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 54
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 49
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 36
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims abstract description 32
- 239000000905 isomalt Substances 0.000 claims abstract description 32
- 235000010439 isomalt Nutrition 0.000 claims abstract description 32
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 27
- 239000002131 composite material Substances 0.000 claims abstract description 25
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 24
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 21
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 21
- 239000011707 mineral Substances 0.000 claims abstract description 21
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 21
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 19
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 19
- 239000004376 Sucralose Substances 0.000 claims abstract description 18
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 18
- 235000019408 sucralose Nutrition 0.000 claims abstract description 18
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 18
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 16
- 239000011720 vitamin B Substances 0.000 claims abstract description 16
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940041616 menthol Drugs 0.000 claims abstract description 14
- 238000013329 compounding Methods 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000011812 mixed powder Substances 0.000 claims description 15
- 230000006872 improvement Effects 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 claims description 3
- NBGXQZRRLOGAJF-UHFFFAOYSA-N Maltulose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)(CO)OCC1O NBGXQZRRLOGAJF-UHFFFAOYSA-N 0.000 claims 1
- 244000126002 Ziziphus vulgaris Species 0.000 claims 1
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 description 15
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 13
- 108010051457 Acid Phosphatase Proteins 0.000 description 13
- 102000013563 Acid Phosphatase Human genes 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 102000003425 Tyrosinase Human genes 0.000 description 11
- 108060008724 Tyrosinase Proteins 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 240000002853 Nelumbo nucifera Species 0.000 description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 4
- 241001247821 Ziziphus Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- -1 sorbierite Chemical compound 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940082632 vitamin b12 and folic acid Drugs 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/362—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种改善人体免疫功能的无糖清口糖,该清口糖由以下原料组成:低聚木糖0.5~2.0份、水苏糖0.3~1.0份、壳寡糖2.0~3.0份、γ‑氨基丁酸1.0~5.0份、红枣提取物3.0~5.0份、蓝莓提取物1.0~2.0份、复合B族维生素0.003~0.008份、复配矿物质0.5~1.5份、三氯蔗糖0.5~1.5份、柠檬酸0.5~2.0份、薄荷脑0.003~0.01份、硬脂酸镁0.5~1.0份、异麦芽酮糖醇70~90份、食用香精0.1~1.0份。本发明还涉及上述清口糖的制备方法,包括粉碎、混合、压片等步骤。该方法工艺简单,操作方便,产品质量稳定、易于携带。
Description
技术领域
本发明涉及一种食用健康糖,具体涉及一种改善人体免疫功能的无糖清口糖。
背景技术
无糖食品,一般是指不含蔗糖(甘蔗糖和甜菜糖)、葡萄糖、麦芽糖、果糖等的甜味食品,但是无糖食品应含有糖醇(包括木糖醇、山梨醇、麦芽糖醇、甘露醇)等替代品。根据国家标准《预包装特殊膳食用食品标签通则》规定,“无糖”的要求是指固体或液体食品中每100克或100毫升的含糖量不高于0.5克。
水苏糖是天然存在的一种四糖,是一种可以显著促进双歧杆菌等有益菌增殖的功能性低聚糖。纯品为白色粉末,味稍甜。水苏糖对人体胃肠道内的双歧杆菌、乳酸杆菌等有益菌群有着极明显的增殖作用,能迅速改善人体消化道内环境,调节微生态菌群平衡。它能促进形成有益菌在消化道内的优势菌地位,抑制产气产酸梭状芽孢杆菌等腐败菌的生产,另外产生大量生理活性物质,调节肠道pH值、灭杀致病菌,阻遏腐败产物生成,抑制内源致癌物的产生和吸收,并且分解衍生出多重免疫功能因子。俗称:有益菌的食物。
壳寡糖又叫壳聚寡糖、低聚壳聚糖,是将壳聚糖经特殊的生物酶技术(也有使用化学降解、微波降解技术的报道)降解得到的一种聚合度在2~20之间寡糖产品,具有壳聚糖所没有的较高溶解度,全溶于水,容易被生物体吸收利用等诸多独特的功能,其作用为壳聚糖的14倍。壳寡糖是自然界中唯一带正电荷阳离子碱性氨基低聚糖,是动物性纤维素。研究证明:壳寡糖具有提高免疫,抑制癌肿细胞生长,促进肝脾抗体形成,促进钙及矿物质的吸收,增殖双歧杆菌、乳酸菌等人体有益菌群,降血脂、降血压、降血糖、调节胆固醇,减肥,预防成人疾病等功能,可应用于医药、功能性食品等领域。壳寡糖可明显消除人体氧负离子自由基,活化机体细胞,延缓衰老,抑制皮肤表面有害菌滋生,保湿性能优异。壳寡糖不但具备水溶性,使用方便,而且抑制腐败菌性能效果显著,兼备多种功能作用。2007年1月,《国民经济与社会发展第十一个五年规划纲要》中“国家公众营养改善计划”实施的第一个公众营养改善项目即国家发改委公众营养改善OLIGO项目正式启动。“壳寡糖与人类未来健康工程”作为OLIGO项目的组成部分,对推动我国公众健康事业的发展起到积极作用,对人民健康具有深远的影响和意义。
γ-氨基丁酸,能促进脑的活化性,健脑益智,抗癫痫,促进睡眠,美容润肤,延缓脑衰老机能,能补充人体抑制性神经递质,具有良好的降血压功效。促进肾机能改善和保护作用。抑制脂肪肝及肥胖症,活化肝功能。每日补充微量的伽玛氨基丁酸有利于心脑血压的缓解,又能促进人体内氨基酸代谢的平衡,调节免疫功能。根据目前的研究,发现GABA的生理活性主要表现在以下几方面:(1)镇静神经、抗焦虑。医学家已经证明GABA是中枢神经系统的抑制性传递物质,是脑组织中最重要的神经递质之一。(2)降低血压。GABA能作用于脊髓的血管运动中枢,有效促进血管扩张,达到降低血压的目的。(3)治疗疾病。日本大阪大学医学院的研究显示GABA对Kupperman综合症具有显著的改善效果。(4)降低血氨。我国的临床医学和日本的研究者也都认为,GABA能抑制谷氨酸的脱羧反应,使血氨降低。更多的谷氨酸与氨结合生成尿素排出体外,以解除氨毒,从而增进肝机能。(5)提高脑活力。GABA能进入脑内三羧酸循环,促进脑细胞代谢,同时还能提高葡萄糖代谢时葡萄糖磷酸酯酶的活性,增加乙酰胆碱的生成,扩张血管增加血流量,并降低血氨,促进大脑的新陈代谢,恢复脑细胞功能。(6)促进乙醇代谢。以嗜酒者为对象,服用GABA再饮用60ml威士忌后采血测定血中乙醇及乙醛浓度,发现后者浓度明显比对照组低。
红枣中的cAMP在生物体内参与细胞分裂与分化、形态形成、糖原和脂肪分解、类固醇生成等多种生理生化过程,并可作用于基因转录,影响蛋白质的合成。更重要的是cAMP对治疗各种肿瘤有显著疗效,能有效阻止人体中亚硝酸盐类物质的形成,从而抑制癌细胞的形成与增殖,甚至可使癌细胞向正常细胞转化的物质,另外,红枣中丰富的维生素C有很强的抗氧化活性及促进胶原蛋白合成的作用,可参与组织细胞的氧化还原反应,与体内多种物质的代谢有关,充足的维生素C能够促进生长发育、增强体力、减轻疲劳降血压、降胆固醇。
蓝莓具有保护视力,防止失明、青光明、白内障、视网膜出血、改善近视、黄斑退化、糖尿病性网膜症、色素性视网膜炎及夜盲症等功效。增加毛细血管的柔韧性,可以纯净促进血管膨胀和伸缩性,防止血管破裂。提供抗氧化剂,能消除使血管硬化的自由基,预防动脉硬化。既能强化眼睛里的毛细血管,当然也能强化身体其他器官组织里的毛细血管,达到预防各部器官血管病变。消灭自由基,当自由基侵害了细胞里的DNA〔去氧核糖核酸〕时,便是癌症的开始。蓝莓是一种抗氧化剂,它是自由基的克星,它是清除自由基的清道夫。
复合维生素B包括维生素B1、维生素B2、维生素B6、维生素B12、烟酸、泛酸、叶酸等。B族维生素是推动体内代谢,把糖、脂肪、蛋白质等转化成热量时不可缺少的物质。如果缺少维生素B,则细胞功能马上降低,引起代谢障碍,这时人体会出现怠滞和食欲不振。复合维生素B协同机体各种酶来完成其功能:其中包括协助碳水化合物和脂肪释放能量、分解氨基酸及输送含有营养素的氧及能量到整个机体。而维生素B6、维生素B12和叶酸,对我们的心脏和思维能力的保护作用则更令人称奇。
发明内容
本发明要解决的技术问题是提供一种改善人体免疫功能的无糖清口糖,具有良好的低热量、非龋齿性能,改善肠道菌群、促进矿物质的吸收,提升人体免疫力,不易被人体所吸收,适合糖尿病人、肥胖人群、想减肥的人们的需求。
本发明所要解决的另一个技术问题是提供一种上述清口糖的制备方法,使其生产工艺简单,操作方便,制得的清口糖质量稳定,易于携带。
为了解决上述技术问题,本发明采用下列技术方案:
一种改善人体免疫功能的无糖清口糖,由以下质量份数的原料制备而成:低聚木糖0.5~2.0份、水苏糖0.3~1.0份、壳寡糖2.0~3.0份、γ-氨基丁酸1.0~5.0份、红枣提取物3.0~5.0份、蓝莓提取物1.0~2.0份、复合B族维生素0.003~0.008份、复配矿物质0.5~1.5份、三氯蔗糖0.5~1.5份、柠檬酸0.5~2.0份、薄荷脑0.003~0.01份、硬脂酸镁0.5~1.0份、异麦芽酮糖醇70~90份、食用香精0.1~1.0份。
其中,所述食用香精选自黑莓香精、苹果香精、柠檬香精中的一种或几种。
优选地,低聚木糖0.8份、水苏糖0.5份、壳寡糖2.4份、γ-氨基丁酸2.8份、红枣提取物3.6份、蓝莓提取物1.4份、复合B族维生素0.006份、复配矿物质0.8份、三氯蔗糖0.9份、柠檬酸0.8份、薄荷脑0.006份、硬脂酸镁0.8份、异麦芽酮糖醇88份、食用香精0.2份。
所述的一种改善人体免疫功能的无糖清口糖的制备方法,其特征在于,所述制备方法由以下步骤组成:
(1)分别称取三氯蔗糖、柠檬酸、薄荷脑、低聚木糖、水苏糖、壳寡糖、γ-氨基丁酸、红枣提取物、蓝莓提取物、复合矿物质、硬脂酸镁,粉碎并过80-100目筛备用,称取复合B族维生素、食用香精备用;
(2)取步骤(1)制得的低聚木糖、水苏糖、壳寡糖、复合矿物质,加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(1);
(3)取步骤(1)制得的γ-氨基丁酸、红枣提取物、蓝莓提取物、复合B族维生素、薄荷脑,加入加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(2);
(4)将三氯蔗糖、柠檬酸、混合粉料(1)(2)、硬脂酸镁、其余异麦芽酮糖醇、食用香精混合均匀,压片,即得产品。
本发明与现有技术相比具有具有以下有益效果:
1、本发明通过低聚木糖、水苏糖、壳聚糖,复合矿物质的复配改善肠道菌群、促进矿物质的吸收,提升人体免疫力。γ--氨基丁酸、红枣提取物、蓝莓提取物、复合B族维生素组合的协同作用,使该产品具有出色的清除人体自由基、抗氧化、舒缓人体紧张情绪、减轻身心压力,同时能够减轻疲劳;促进人体内氨基酸代谢平衡,调节人体机能,改善睡眠,提高记忆力,从而提高人体的免疫功能。
2、本发明清口糖具有清新口气,醒脑的作用,不仅适合普通人群食用,还特别适合糖尿病患者、肥胖病人或者希望减肥的人群食用,同时,也满足高强度脑力工作者的需求。
增强记忆功能的作用,可通过以下试验证明:
试验例1通过避暗试验证明本发明清口糖对小白鼠记忆力的影响
1、材料
1.1动物普通级小白鼠40只,体重质量280-300g,雌雄各半。
1.2供试清口糖按实施例3自制。试验时,用生理盐水溶解制成各种浓度的供试液。
2、方法
2.1分组将40只小白鼠随即均匀分为大、中、小计量清口糖组(2g、1g、0.5g)、空白组,每组10只,雌雄各半。
2.2将各组小白鼠背对洞口放入明室,启动计时器,记录小白鼠由明室进入暗室的时间,暗室中放置香油,待小白鼠进入暗室后,通电刺激2s,电激后5s取出小白鼠,归回饲养笼。训练后24小时,各组小白鼠每天用药1次,连续用药10天,空白组不予处理。于用药后的第11天,再将各组小白鼠对洞口置于明室,同时开启计时器,记录各组小白鼠第一次进入暗室时间,为潜伏期(STL),观察5min,始终未进入的小白鼠STL规定为300s。
2.3计算各组小白鼠由明室进入按时的时间平均值,比较用药量对小白鼠记忆力的影响。
3、实验结果
试验结果见表1:空白组由明室进入暗室的潜伏期明显短于清口糖各计量组,并且中剂量组小白鼠由明室进入暗室的潜伏期最长,说明该剂量对小白鼠的记忆力影响最大,其次是大剂量组和小剂量组。
表1本发明清口糖对小白鼠记忆力的影响
与空白组相比,*p<0.05,**p<0.01
提高免疫力的作用,可通过以下试验证明:
试验例2:测定药物对小白鼠体液免疫功能的影响
1、材料
1.1动物普通级小白鼠40只,体重质量250-300g,雌雄各半。
1.2供试清口糖按实施例3自制。
2、方法
2.1分组将40只小白鼠随即均匀分为对照组、大、中、小计量清口糖组(2g、1g、0.5g),每组10只,雌雄各半。
2.2将各组小白鼠放置在饲养槽内,大、中、小计量组喂投添加了固定计量供试清口糖的饲料,对照组喂投不添加清口糖的饲料,试验第10天喂投后1小时,从每组试验小白鼠中抽取血淋巴。
2.3测定免疫指标血清酚氧化酶(PO)活力及血清酸性磷酸酶(ACP)活力。
3、试验结果
免疫指标血清酚氧化酶(PO)活力试验结果见表2:
由上表可看出,用中剂量组小白鼠免疫指标血清酚氧化酶(PO)活力最大,说明该剂量对小白鼠的免疫指标血清酚氧化酶影响最大,其次是大剂量组和小剂量组。
血清酸性磷酸酶(ACP)活力见表3
表3血清酸性磷酸酶(ACP)活力
与空白组相比,*p<0.05,**p<0.01
由上表可看出,用中剂量组小白鼠血清酸性磷酸酶(ACP)活力最大,说明该剂量对小白鼠的血清酸性磷酸酶影响最大,其次是大剂量组和小剂量组。
为了更好的阐述本技术方案,下面结合具体实施方式对本发明做进一步的说明,但本发明所要求的保护范围不限于下列实施例。
具体实施方式
下面结合实施例,对本发明作进一步地描述。
实施例1:
配方:
低聚木糖0.5份、水苏糖0.3份、壳寡糖2.0份、γ-氨基丁酸2.0份、红枣提取物3.0份、蓝莓提取物1.0份、复合B族维生素0.003份、复配矿物质1.5份、三氯蔗糖0.5份、柠檬酸0.5份、薄荷脑0.003份、硬脂酸镁0.5份、异麦芽酮糖醇90份、黑莓香精0.4份。
制法:
(1)分别称取三氯蔗糖、柠檬酸、薄荷脑、低聚木糖、水苏糖、壳寡糖、γ-氨基丁酸、红枣提取物、蓝莓提取物、复合矿物质、硬脂酸镁,粉碎并过80-100目筛备用,称取复合B族维生素、食用香精备用;
(2)取步骤(1)制得的低聚木糖、水苏糖、壳寡糖、复合矿物质,加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(1);
(3)取步骤(1)制得的γ-氨基丁酸、红枣提取物、蓝莓提取物、复合B族维生素、薄荷脑,加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(2);
(4)将三氯蔗糖、柠檬酸、混合粉料(1)(2)、硬脂酸镁、其余异麦芽酮糖醇、食用香精混合均匀,压片,即得产品。
试验方法参照试验例1,结果见下表,结果表明本实施例制成的改善人体免疫功能的无糖清口糖能够提高小白鼠的记忆力。
表4本发明清口糖对小白鼠记忆力的影响
表5免疫指标血清酚氧化酶(PO)活力试验结果
表6血清酸性磷酸酶(ACP)活力
实施例2:
配方:
低聚木糖2.0份、水苏糖1.0份、壳寡糖3.0份、γ-氨基丁酸4.5份、红枣提取物5.0份、蓝莓提取物2.0份、复合B族维生素0.008份、复配矿物质1.5份、三氯蔗糖1.2份、柠檬酸2.0份、薄荷脑0.09份、硬脂酸镁1.0份、异麦芽酮糖醇75份、苹果香精0.8份。
制法:
(1)分别称取三氯蔗糖、柠檬酸、薄荷脑、低聚木糖、水苏糖、壳寡糖、γ-氨基丁酸、红枣提取物、蓝莓提取物、复合矿物质、硬脂酸镁,粉碎并过80-100目筛备用,称取复合B族维生素、食用香精备用;
(4)取步骤(1)制得的低聚木糖、水苏糖、壳寡糖、复合矿物质,加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(1);
(5)取步骤(1)制得的γ-氨基丁酸、红枣提取物、蓝莓提取物、复合B族维生素、薄荷脑,加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(2);
(6)将三氯蔗糖、柠檬酸、混合粉料(1)(2)、硬脂酸镁、其余异麦芽酮糖醇、食用香精混合均匀,压片,即得产品。
试验方法参照试验例1,结果见下表,结果表明本实施例制成的改善人体免疫功能的无糖清口糖能够提高小白鼠的记忆力。
表7本发明清口糖对小白鼠记忆力的影响
表8免疫指标血清酚氧化酶(PO)活力试验结果
表9血清酸性磷酸酶(ACP)活力
实施例3:
配方:
低聚木糖0.8份、水苏糖0.5份、壳寡糖2.4份、γ-氨基丁酸2.8份、红枣提取物3.6份、蓝莓提取物1.4份、复合B族维生素0.006份、复配矿物质0.8份、三氯蔗糖0.9份、柠檬酸0.8份、薄荷脑0.006份、硬脂酸镁0.8份、异麦芽酮糖醇88份、柠檬香精0.2份。
制法:
(1)分别称取三氯蔗糖、柠檬酸、薄荷脑、低聚木糖、水苏糖、壳寡糖、γ-氨基丁酸、红枣提取物、蓝莓提取物、复合矿物质、硬脂酸镁,粉碎并过80-100目筛备用,称取复合B族维生素、食用香精备用;
(4)取步骤(1)制得的低聚木糖、水苏糖、壳寡糖、复合矿物质,加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(1);
(5)取步骤(1)制得的γ-氨基丁酸、红枣提取物、蓝莓提取物、复合B族维生素、薄荷脑,加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(2);
(6)将三氯蔗糖、柠檬酸、混合粉料(1)(2)、硬脂酸镁、其余异麦芽酮糖醇、食用香精混合均匀,压片,即得产品。
试验结果见试验例1和试验例2。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (4)
1.一种改善人体免疫功能的无糖清口糖,其特征在于,所述清口糖由以下质量份数的原料制备而成:低聚木糖0.5~2.0份、水苏糖0.3~1.0份、壳寡糖2.0~3.0份、γ-氨基丁酸1.0~5.0份、红枣提取物3.0~5.0份、蓝莓提取物1.0~2.0份、复合B族维生素0.003~0.008份、复配矿物质0.5~1.5份、三氯蔗糖0.5~1.5份、柠檬酸0.5~2.0份、薄荷脑0.003~0.01份、硬脂酸镁0.5~1.0份、异麦芽酮糖醇70~90份、食用香精0.1~1.0份。
2.根据权利要求1所述的一种改善人体免疫功能的无糖清口糖,其特征在于,所述食用香精选自黑莓香精、苹果香精、柠檬香精中的一种或几种。
3.根据权利要求1-2任一项所述的一种改善人体免疫功能的无糖清口糖,其特征在于,所述清口糖由以下质量份数的原料制备而成:低聚木糖0.8份、水苏糖0.5份、壳寡糖2.4份、γ-氨基丁酸2.8份、红枣提取物3.6份、蓝莓提取物1.4份、复合B族维生素0.006份、复配矿物质0.8份、三氯蔗糖0.9份、柠檬酸0.8份、薄荷脑0.006份、硬脂酸镁0.8份、异麦芽酮糖醇88份、食用香精0.2份。
4.根据权利要求1所述的一种改善人体免疫功能的无糖清口糖的制备方法,其特征在于,所述制备方法由以下步骤组成:
(1)分别称取三氯蔗糖、柠檬酸、薄荷脑、低聚木糖、水苏糖、壳寡糖、γ-氨基丁酸、红枣提取物、蓝莓提取物、复合矿物质、硬脂酸镁,粉碎并过80-100目筛备用,称取复合B族维生素、食用香精备用;
(2)取步骤(1)制得的低聚木糖、水苏糖、壳寡糖、复合矿物质,加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(1);
(3)取步骤(1)制得的γ-氨基丁酸、红枣提取物、蓝莓提取物、复合B族维生素、薄荷脑,加入加入粒度为60-70目的异麦芽酮糖醇,该步骤中异麦芽酮糖醇加入量为其配方总用量的10%,经充分搅拌,混合均匀,得混合粉料(2);
(4)将三氯蔗糖、柠檬酸、混合粉料(1)(2)、硬脂酸镁、其余异麦芽酮糖醇、食用香精混合均匀,压片,即得产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710325241.7A CN107156411A (zh) | 2017-05-10 | 2017-05-10 | 一种改善人体免疫功能的无糖清口糖 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710325241.7A CN107156411A (zh) | 2017-05-10 | 2017-05-10 | 一种改善人体免疫功能的无糖清口糖 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107156411A true CN107156411A (zh) | 2017-09-15 |
Family
ID=59813616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710325241.7A Pending CN107156411A (zh) | 2017-05-10 | 2017-05-10 | 一种改善人体免疫功能的无糖清口糖 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107156411A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105028854A (zh) * | 2015-07-13 | 2015-11-11 | 天津世纪天龙药业有限公司 | 氨基酸玛卡压片糖果及其制备方法与用途 |
CN105211481A (zh) * | 2015-11-10 | 2016-01-06 | 苏州工业园区尚融科技有限公司 | 一种玛卡益生元无糖清口糖及其制备方法 |
CN105211483A (zh) * | 2015-11-10 | 2016-01-06 | 苏州尚融生物技术有限公司 | 一种具有回苦味的无糖清口糖及其制备方法 |
CN105285282A (zh) * | 2015-11-10 | 2016-02-03 | 苏州尚融生物技术有限公司 | 一种益生元无糖清口糖及其制备方法 |
CN106490284A (zh) * | 2016-11-03 | 2017-03-15 | 吉林师范大学博达学院 | 一种缓解压力的糖果及其制备方法 |
CN106605918A (zh) * | 2015-10-22 | 2017-05-03 | 石家庄以岭药业股份有限公司 | 一种含有γ-氨基丁酸的咀嚼片及其制备方法 |
-
2017
- 2017-05-10 CN CN201710325241.7A patent/CN107156411A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105028854A (zh) * | 2015-07-13 | 2015-11-11 | 天津世纪天龙药业有限公司 | 氨基酸玛卡压片糖果及其制备方法与用途 |
CN106605918A (zh) * | 2015-10-22 | 2017-05-03 | 石家庄以岭药业股份有限公司 | 一种含有γ-氨基丁酸的咀嚼片及其制备方法 |
CN105211481A (zh) * | 2015-11-10 | 2016-01-06 | 苏州工业园区尚融科技有限公司 | 一种玛卡益生元无糖清口糖及其制备方法 |
CN105211483A (zh) * | 2015-11-10 | 2016-01-06 | 苏州尚融生物技术有限公司 | 一种具有回苦味的无糖清口糖及其制备方法 |
CN105285282A (zh) * | 2015-11-10 | 2016-02-03 | 苏州尚融生物技术有限公司 | 一种益生元无糖清口糖及其制备方法 |
CN106490284A (zh) * | 2016-11-03 | 2017-03-15 | 吉林师范大学博达学院 | 一种缓解压力的糖果及其制备方法 |
Non-Patent Citations (3)
Title |
---|
张忠盛 等: "《新型糖果生产工艺与配方》", 28 February 2014, 中国轻工业出版社 * |
杨月欣 等: "《营养功能成分应用指南》", 30 June 2011, 北京大学医学出版社 * |
王昌涛 等: "《蓝莓综合加工与应用》", 31 March 2013, 中国农业科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101248900B (zh) | 一种新型固体运动饮料冲剂 | |
CN102389116B (zh) | 一种能够缓解体力疲劳的泡腾片及其制备工艺 | |
CN102224891B (zh) | 一种糖醇蜂蜜苹果酱及其制备方法 | |
CN101889679B (zh) | 一种具有解酒保肝作用的组合物及其在食品、保健食品中的应用 | |
CN101766635B (zh) | 解酒醒酒组合物 | |
CN102160664A (zh) | 儿童营养饮料 | |
CN103349284A (zh) | 一种桑椹酵素营养液及其制备方法 | |
CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
CN106993788A (zh) | 全天然蜂王浆含片及其制备方法 | |
CN107411065A (zh) | 一种菊芋酵素及其制备方法、制剂与应用 | |
CN101766715B (zh) | 解酒醒酒组合物 | |
US20030104107A1 (en) | Energy drink formula and method | |
CN101766672B (zh) | 解酒醒酒组合物 | |
CN107252095A (zh) | 复合酵素及其制备方法 | |
CN113349377A (zh) | 一种瘦身益生菌软胶囊及其制备方法 | |
CN101766637B (zh) | 解酒醒酒组合物 | |
CN108902719A (zh) | 一种保健面条及其制备方法 | |
CN105707378A (zh) | 黑青稞瘦身咖啡 | |
CN102273581A (zh) | 一种高甜度复配甜味剂 | |
JP3433917B2 (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
CN116210831A (zh) | 一种助睡眠火龙果发酵饮品及其制备方法 | |
CN109700031A (zh) | 用于肠道清洁、肠道排毒的营养组合物 | |
CN107439866A (zh) | 枸杞鹰嘴豆植物营养素饮料及其制备工艺 | |
CN107156411A (zh) | 一种改善人体免疫功能的无糖清口糖 | |
CN100392058C (zh) | 含纳米sod的果酒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170915 |
|
RJ01 | Rejection of invention patent application after publication |